151 related articles for article (PubMed ID: 14606355)
1. [Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans].
Baars A; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2072-6. PubMed ID: 14606355
[TBL] [Abstract][Full Text] [Related]
2. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
3. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans].
Moiseenko VM; Chudenko VA; Orlova RV; Imianitov EN; Matsko DE; Gafton GI; Kochnev VA; Protsenko SA; Mikhaĭlichenko TD; Nogaeva TKh
Vopr Onkol; 2008; 54(5):656-60. PubMed ID: 19069485
[No Abstract] [Full Text] [Related]
6. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Scheinfeld N
J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
[TBL] [Abstract][Full Text] [Related]
8. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy.
Mehrany K; Swanson NA; Heinrich MC; Weenig RH; Lee KK; White CR; Devere TS
Dermatol Surg; 2006 Mar; 32(3):456-9. PubMed ID: 16640697
[No Abstract] [Full Text] [Related]
9. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
[TBL] [Abstract][Full Text] [Related]
10. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
Mizutani K; Tamada Y; Hara K; Tsuzuki T; Saeki H; Tamaki K; Matsumoto Y
Br J Dermatol; 2004 Jul; 151(1):235-7. PubMed ID: 15270901
[No Abstract] [Full Text] [Related]
12. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
McArthur GA
Curr Opin Oncol; 2006 Jul; 18(4):341-6. PubMed ID: 16721128
[TBL] [Abstract][Full Text] [Related]
13. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results.
Malhotra B; Schuetze SM
Curr Opin Oncol; 2012 Jul; 24(4):419-24. PubMed ID: 22510939
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
[TBL] [Abstract][Full Text] [Related]
16. Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient.
Fava P; Stroppiana E; Savoia P; Bernengo MG
J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):244-5. PubMed ID: 19694892
[No Abstract] [Full Text] [Related]
17. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study.
Savoia P; Ortoncelli M; Quaglino P; Bernengo MG
Dermatol Surg; 2006 Aug; 32(8):1097-102. PubMed ID: 16918576
[No Abstract] [Full Text] [Related]
18. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
Wicherts DA; van Coevorden F; Klomp HM; van Huizum MA; Kerst JM; Haas RL; van Boven HH; van der Hage JA
World J Surg Oncol; 2013 Mar; 11():59. PubMed ID: 23496933
[TBL] [Abstract][Full Text] [Related]
19. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
[TBL] [Abstract][Full Text] [Related]
20. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
Johnson-Jahangir H; Sherman W; Ratner D
J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
